Autopsy report · NCT05101213

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

“\<75% participation”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 4 months before it started.
• Ran for about 3 years 7 months before it stopped.
• 12 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Adenovirus Infection; BK Virus Infection; Cytomegaloviral Infection; Hematopoietic and Lymphoid Cell Neoplasm; JC Virus Infection; Malignant Solid Neoplasm

Interventions

Virus-specific Cytotoxic T-lymphocytes

Participants

12

Sites

1

Countries

United States

Trials that died the same way

• ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
  “\<75% participants” (87% match in meaning)
• Vapocoolant Analgesia for Breast Lymphoscintigraphy
  “\<75% accrued participants” (76% match in meaning)
• Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery
  “low participation rate” (72% match in meaning)
• Physiotherapy and Therapeutic Education After Total Knee Arthroplasty.
  “low participation” (70% match in meaning)
• Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy
  “Lack of participations (8 of 25)” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.